Sanofi Stock Prediction and Forecast [SNY]

AI-generated source summary

Sanofi (SNY) shows a negative trend with mixed headlines. Recent analyst ratings are predominantly sell/hold, with a few buy signals. While some short-term and long-term technical indicators suggest a bearish outlook with expected resistance at $50.26 and $50.10, there's a positive overall trend observed in the past three months. However, the stock's recent performance, including a drop of -6.09% from a pivot top, and a sustained decline in volume alongside price movement, indicates a sell signal. The stock is currently trading below its 50-day and 200-day moving averages, reinforcing the bearish sentiment. Despite a positive outlook on a new drug indication, the stock is facing legal and reputational risks. The price is currently testing support at $45.65, and a break below this level could lead to further declines. The P/E ratio of 11.54 suggests the stock might be undervalued, but the negative signals and recent price action point towards a short-term bearish outlook.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   25 Nov 2025, 04:42 UTC

   The analyst published the original source item.

2. First prediction resolved

   25 Nov 2025, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   25 Nov 2025, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:14 UTC

   Tahlil Plus began monitoring the extracted predictions.